CN111187836B - 泌尿上皮癌的检测套组及微型核糖核酸组合物在制备用于预测泌尿上皮癌检测套组中的应用 - Google Patents
泌尿上皮癌的检测套组及微型核糖核酸组合物在制备用于预测泌尿上皮癌检测套组中的应用 Download PDFInfo
- Publication number
- CN111187836B CN111187836B CN201910299262.5A CN201910299262A CN111187836B CN 111187836 B CN111187836 B CN 111187836B CN 201910299262 A CN201910299262 A CN 201910299262A CN 111187836 B CN111187836 B CN 111187836B
- Authority
- CN
- China
- Prior art keywords
- mir
- cancer
- ribonucleic acid
- micro ribonucleic
- urothelial cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002477 rna polymer Polymers 0.000 title claims abstract description 65
- 201000009030 Carcinoma Diseases 0.000 title claims description 30
- 230000002485 urinary effect Effects 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title claims description 12
- 238000001514 detection method Methods 0.000 title abstract description 40
- 238000002360 preparation method Methods 0.000 title description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims abstract description 102
- 108091046841 MiR-150 Proteins 0.000 claims abstract description 82
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims abstract description 58
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims abstract description 58
- 108091033773 MiR-155 Proteins 0.000 claims abstract description 46
- 108091028067 miR-19b-1 stem-loop Proteins 0.000 claims abstract description 45
- 108091091900 miR-636 stem-loop Proteins 0.000 claims abstract description 43
- 239000000523 sample Substances 0.000 claims abstract description 37
- 239000002253 acid Substances 0.000 claims abstract description 36
- 108091048308 miR-210 stem-loop Proteins 0.000 claims abstract description 31
- 108091029500 miR-183 stem-loop Proteins 0.000 claims abstract description 28
- 108091026308 miR-487 stem-loop Proteins 0.000 claims abstract description 18
- 108700011259 MicroRNAs Proteins 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 15
- 150000007513 acids Chemical class 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000010839 reverse transcription Methods 0.000 claims description 9
- 230000004544 DNA amplification Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 27
- 206010028980 Neoplasm Diseases 0.000 description 28
- 238000011282 treatment Methods 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 14
- 108091070501 miRNA Proteins 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 11
- 239000002679 microRNA Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 210000001635 urinary tract Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 108091058273 miR-487a stem-loop Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000023747 urothelial carcinoma Diseases 0.000 description 4
- 235000012431 wafers Nutrition 0.000 description 4
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 3
- 206010046392 Ureteric cancer Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 3
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 201000011294 ureter cancer Diseases 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 2
- 206010046431 Urethral cancer Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000000360 urethra cancer Diseases 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108091069088 Homo sapiens miR-150 stem-loop Proteins 0.000 description 1
- 108091065981 Homo sapiens miR-155 stem-loop Proteins 0.000 description 1
- 108091067605 Homo sapiens miR-183 stem-loop Proteins 0.000 description 1
- 108091070519 Homo sapiens miR-19b-1 stem-loop Proteins 0.000 description 1
- 108091070495 Homo sapiens miR-19b-2 stem-loop Proteins 0.000 description 1
- 108091067468 Homo sapiens miR-210 stem-loop Proteins 0.000 description 1
- 108091067245 Homo sapiens miR-378a stem-loop Proteins 0.000 description 1
- 108091053832 Homo sapiens miR-487a stem-loop Proteins 0.000 description 1
- 108091061623 Homo sapiens miR-636 stem-loop Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000682 transitional epithelial cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
曲线下面积 | P值 | |
miR-155/miR-150 | 0.751 | 0.004857 |
miR-378/miR-150 | 0.714 | 0.01673 |
miR-636/miR-150 | 0.701 | 0.02436 |
miR-150/miR-210 | 0.685 | 0.03848 |
miR-19b-1/miR-378 | 0.676 | 0.04897 |
miR-19b-1/miR-487a | 0.668 | 0.2200 |
miR-210/miR-183 | 0.658 | 0.012 |
miR-19b-1/miR-155 | 0.656 | 0.215721 |
miR-487a/miR-155 | 0.65 | 0.218336 |
miR-636/miR-487a | 0.644 | 0.098878 |
miR-210/miR-487a | 0.641 | 0.136675 |
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107140464 | 2018-11-14 | ||
TW107140464A TWI690597B (zh) | 2018-11-14 | 2018-11-14 | 泌尿上皮癌的檢測套組及檢測方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111187836A CN111187836A (zh) | 2020-05-22 |
CN111187836B true CN111187836B (zh) | 2024-03-01 |
Family
ID=70550975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910299262.5A Active CN111187836B (zh) | 2018-11-14 | 2019-04-15 | 泌尿上皮癌的检测套组及微型核糖核酸组合物在制备用于预测泌尿上皮癌检测套组中的应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11098371B2 (zh) |
CN (1) | CN111187836B (zh) |
TW (1) | TWI690597B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476947A (zh) * | 2011-03-02 | 2013-12-25 | 格路福生物制药公司 | 寡聚体的增强的生物分布 |
CN108778301A (zh) * | 2016-03-10 | 2018-11-09 | 永恒生物科技股份有限公司 | 通过联合疗法来治疗实体瘤或淋巴瘤的方法 |
CN108884448A (zh) * | 2016-01-27 | 2018-11-23 | 昂克诺斯公司 | 溶瘤病毒载体及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103025384B (zh) * | 2010-03-26 | 2016-04-20 | 俄亥俄州立大学 | 涉及miR-155对于错配修复和基因组稳定性的调节的材料和方法 |
-
2018
- 2018-11-14 TW TW107140464A patent/TWI690597B/zh active
-
2019
- 2019-04-15 CN CN201910299262.5A patent/CN111187836B/zh active Active
- 2019-07-02 US US16/460,546 patent/US11098371B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476947A (zh) * | 2011-03-02 | 2013-12-25 | 格路福生物制药公司 | 寡聚体的增强的生物分布 |
CN108884448A (zh) * | 2016-01-27 | 2018-11-23 | 昂克诺斯公司 | 溶瘤病毒载体及其用途 |
CN108778301A (zh) * | 2016-03-10 | 2018-11-09 | 永恒生物科技股份有限公司 | 通过联合疗法来治疗实体瘤或淋巴瘤的方法 |
Also Published As
Publication number | Publication date |
---|---|
TW202018094A (zh) | 2020-05-16 |
TWI690597B (zh) | 2020-04-11 |
CN111187836A (zh) | 2020-05-22 |
US20200149113A1 (en) | 2020-05-14 |
US11098371B2 (en) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9920375B2 (en) | Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers | |
WO2017202185A1 (zh) | 甄别肺部微小结节良恶性的外周血基因标志物及其用途 | |
CN114277143B (zh) | 外泌体arpc5、cda等在肺癌诊断中的应用 | |
CN104694623A (zh) | 一种用于肺癌诊断的血浆miRNA标志物及应用 | |
CN111455053B (zh) | 用于结直肠腺瘤诊断的外泌体rna分子标记物组合及其应用 | |
CN113337613A (zh) | 一种与肝癌相关的血清外泌体tsRNA标志物、探针及其应用 | |
TWI571514B (zh) | 評估罹患大腸直腸癌風險的方法 | |
CN111187836B (zh) | 泌尿上皮癌的检测套组及微型核糖核酸组合物在制备用于预测泌尿上皮癌检测套组中的应用 | |
CN110331207A (zh) | 肺腺癌生物标志物及相关应用 | |
CN107326092B (zh) | 大肠癌相关的miRNA作为生物标志物的应用及大肠癌检测试剂盒 | |
WO2017167034A1 (zh) | 膀胱癌检测方法及套组 | |
CN112646876A (zh) | 用于银屑病诊断的miRNA及其应用 | |
WO2024062867A1 (ja) | 対象のがん罹患の可能性を分析する方法 | |
TWI626314B (zh) | 評估罹患大腸直腸癌風險的方法 | |
TWI718474B (zh) | 評估個體罹患泌尿上皮癌之風險的方法及其套組 | |
CN109988834A (zh) | 血浆外泌体分子标志物has-miR-219a-5p及应用 | |
CN114214422B (zh) | 外泌体miR-106b-3P、ARPC5在肺癌诊断中的应用 | |
CN116287252B (zh) | 长链非编码rna apcdd1l-dt在制备检测胰腺癌的产品中的应用 | |
CN112877435B (zh) | 口腔鳞癌生物标志物及其应用 | |
WO2015101342A1 (zh) | 体外辅助诊断胰腺癌的试剂盒和方法 | |
CN116083583A (zh) | miRNA-483-5p在制备胰腺癌肝转移诊断试剂盒中的应用 | |
TWI640635B (zh) | 膀胱癌檢測方法及套組 | |
CN108220427A (zh) | 一种用于鉴别诊断BHD综合征与原发性自发性气胸的血浆microRNA标记物及应用 | |
CN111500716A (zh) | 评估个体罹患泌尿上皮癌之风险的方法及其试剂盒 | |
CN113801928A (zh) | 评估个体罹患腹膜硬化症风险的方法、其分析器及其套组 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220428 Address after: Taiwan District of Zhongli City, Taoyuan Chinese Road No. 300 Applicant after: Ma Nianhan Applicant after: Zhang Huanzhen Applicant after: DELTA ELECTRONICS, Inc. Address before: China Taiwan Taoyuan Ping Township Guangtai Road No. 77 Applicant before: Zhang Huanzhen Applicant before: DELTA ELECTRONICS, Inc. Effective date of registration: 20220428 Address after: China Taiwan Taoyuan Ping Township Guangtai Road No. 77 Applicant after: Zhang Huanzhen Applicant after: DELTA ELECTRONICS, Inc. Address before: The road China Taiwan Taoyuan County in Zhongli City, No. 300 Applicant before: National Central University Applicant before: Zhang Huanzhen Applicant before: DELTA ELECTRONICS, Inc. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |